AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) — Aspira Girls’s Well being Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical primarily based ladies’s well being firm targeted on gynecologic illness, as we speak introduced it has commenced an underwritten public providing of shares of its widespread inventory and warrants to buy shares of its widespread inventory. The providing is topic to market and different situations, and there could be no assurance as as to if or when the providing could also be accomplished, or as to the precise measurement or phrases of the providing. All the securities will probably be provided by Aspira.
William Blair & Firm, L.L.C. is appearing as the only book-running supervisor for the proposed providing.
Aspira intends to make use of the web proceeds from the providing for working capital and different common company functions, together with product portfolio enlargement and commercialization. Aspira can also use a portion of the web proceeds from the providing to spend money on complimentary companies, strategic partnerships, applied sciences or different mental property.
The providing is being made pursuant to a shelf registration assertion (File No. 333-252267) beforehand filed with, and declared efficient by, the U.S. Securities and Change Fee (the “SEC”). A preliminary prospectus complement, dated August 22, 2022, and accompanying prospectus, dated January 28, 2021, referring to the providing will probably be filed with the SEC and will probably be accessible on the SEC’s web site at www.sec.gov. To acquire a replica of the preliminary prospectus complement and the ultimate prospectus complement (when accessible) for the providing, please contact William Blair & Firm, L.L.C., Consideration: Prospectus Division, 150 North Riverside Plaza, Chicago, IL 60606, by phone at 1-800-621-0687 or by e-mail at [email protected].
This press launch is for informational functions solely and shall not represent a suggestion to promote or a solicitation of a suggestion to purchase securities in any state or different jurisdiction wherein such provide or sale isn’t permitted.
About Aspira Girls’s Well being Inc.
Aspira Girls’s Well being Inc. (Nasdaq: AWH) is reworking ladies’s well being with the invention, growth, and commercialization of revolutionary testing choices and bio-analytical options that assist physicians assess danger, optimize affected person administration and enhance gynecologic well being outcomes for girls. Aspira Girls’s Well being is especially targeted on closing the ethnic disparity hole in ovarian most cancers danger evaluation and creating options for pelvic ailments reminiscent of pelvic mass danger evaluation and endometriosis. OVA1plus™ combines our FDA-cleared merchandise, OVA1® and OVERA®, to detect danger of ovarian malignancy in ladies with adnexal lots. Aspira GenetiX™ testing presents each focused and complete genetic testing choices with a gynecologic focus. The subsequent technology of merchandise in growth embrace OVAWatch™ and EndoCheck™.
Ahead Wanting Statements
This press launch comprises forward-looking statements, as outlined within the Personal Securities Litigation Reform Act of 1995. All statements aside from statements of historic information contained on this press launch are forward-looking statements, together with, with out limitation, statements relating to the completion, timing and measurement of the proposed public providing, in addition to the anticipated use of proceeds therefrom. Phrases reminiscent of “might,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “might,” “ought to,” “proceed,” “will,” “potential,” “initiatives” and related expressions are meant to determine forward-looking statements. These forward-looking statements communicate solely as of the date of this press launch and are topic to plenty of dangers, uncertainties and assumptions, together with the dangers and uncertainties related to market situations and satisfaction of customary closing situations associated to the proposed public providing, in addition to dangers and uncertainties inherent in Aspira’s enterprise, together with these described within the part entitled “Danger Components” in Aspira’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2021, as supplemented by the part entitled “Danger Components” in Aspira’s Quarterly Report on Kind 10-Q for the quarter ended June 30, 2022, and in Aspira’s different periodic filings with the SEC. The occasions and circumstances mirrored in Aspira’s forward-looking statements will not be achieved or happen and precise outcomes might differ materially from these projected within the forward-looking statements. Aspira expressly disclaims any obligation to replace, amend or make clear any forward-looking statements to mirror occasions, new data or circumstances occurring after the date of this press launch, besides as required by legislation.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC